{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:51Z","timestamp":1783696671456,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nrleng.2026.502076","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:21:27Z","timestamp":1779466887000},"page":"502076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus statement and clinical recommendations on the practical management of lipid-lowering therapy in stroke and transient ischaemic attack"],"prefix":"10.1016","volume":"41","author":[{"given":"M.","family":"Freijo-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Torres-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gil-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guill\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Palacio-Portilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Purroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Masjuan Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.502076_bib0005","series-title":"Estrategia en Ictus del Sistema Nacional de Salud. Actualizaci\u00f3n 2024","year":"2025"},{"key":"10.1016\/j.nrleng.2026.502076_bib0010","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1804492","article-title":"Global, regional, and country-specific lifetime risks ofstroke, 1990 and 2016","volume":"379","author":"Feigin","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0015","series-title":"Defunciones seg\u00fan la causa de muerte m\u00e1s frecuente - Resultados definitivos 2024","year":"2025"},{"key":"10.1016\/j.nrleng.2026.502076_bib0020","article-title":"Logros y retos en la atenci\u00f3n del ictus en Espa\u00f1a: desde la estrategia del sistema nacional de salud al plan de acci\u00f3n europeo 2018-2030","volume":"95","author":"Simal-Hern\u00e1ndez","year":"2021","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"10.1016\/j.nrleng.2026.502076_bib0025","series-title":"Department of Economic and Social Affairs, Population Division (2017). World Population Ageing 2017(ST\/ESA\/SER.A\/408)","year":"2025"},{"key":"10.1016\/j.nrleng.2026.502076_bib0030","unstructured":"Sociedad Espa\u02dcnola de Neurolog\u00eda (SEN). Impacto socio-sanitario de las enfermedades neurol\u00f3gicas en Espa\u00f1a, 2025 [Accessed March 2025]. Available from: https:\/\/www.sen.es\/pdf\/2024\/Informe_sociosanitario_2024.pdf."},{"key":"10.1016\/j.nrleng.2026.502076_bib0035","unstructured":"Sociedad Espa\u02dcnola de Neurolog\u00eda (SEN). Atlas del ictus enEspa\u02dcna 2019, 2019 [Accessed March 2025]. Available from: https:\/\/www.sen.es\/images\/2020\/atlas\/Atlas_del_Ictus_de_Espana_version_web.pdf."},{"key":"10.1016\/j.nrleng.2026.502076_bib0040","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta Nacional de Saludde Espa\u02dcna 2011\/12, 2012 [Accessed March 2025]. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/encuestaNacional\/encuesta2011.htm."},{"key":"10.1016\/j.nrleng.2026.502076_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nrl.2018.11.002","article-title":"Evoluci\u00f3n del gasto en servicios sanitarios antes y despu\u00e9s del ictus isqu\u00e9mico: an\u00e1lisis de base poblacional","volume":"37","author":"Ribera","year":"2022","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrleng.2026.502076_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.aprim.2023.102578","article-title":"Organizaci\u00f3n y costes de la atenci\u00f3n extrahospitalaria del ictus. Revisi\u00f3n sistem\u00e1tica de la literatura","volume":"55","author":"Lucas-Noll","year":"2023","journal-title":"Atenci\u00f3n Primaria"},{"key":"10.1016\/j.nrleng.2026.502076_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10198-016-0799-9","article-title":"Economic impact of patients admitted to stroke units in Spain","volume":"18","author":"Alvarez-Sab\u00edn","year":"2017","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.nrleng.2026.502076_bib0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O\u2019Donnell","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2026.502076_bib0065","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.nrleng.2026.502076_bib0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0075","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nrl.2020.07.027","article-title":"Dislipidemias y prevenci\u00f3n del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espa\u00f1ola de Neurolog\u00eda","volume":"37","author":"Palacio-Portilla","year":"2022","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrleng.2026.502076_bib0095","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0100","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/2047487319830503","article-title":"Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials","volume":"28","author":"Shin","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0105","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/STROKEAHA.119.028718","article-title":"Benefit of targeting a LDL (Low-density lipoprotein) cholesterol <70 mg\/dL during 5 years after ischemic stroke","volume":"51","author":"Amarenco","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0120","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved reduction of outcomes: Vytorin efficacy international trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.502076_bib0125","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0130","first-page":"310","article-title":"Uso de nuevas terapias hipolipemiantes en la pr\u00e1ctica cl\u00ednica. Consenso SEC\/SEA\/SEEN\/SEMFYC\/SEMERGEN\/SEMG\/SEN\/SEACV\/S.E.N","volume":"59","author":"Vivas","year":"2024","journal-title":"REC: CardioClinics"},{"key":"10.1016\/j.nrleng.2026.502076_bib0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","article-title":"Risk and cumulative risk of stroke recurrence","volume":"42","author":"Mohan","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0145","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1161\/STROKEAHA.120.029972","article-title":"Twenty-year time trends in long-term case-fatality and recurrence rates after ischemic stroke stratified by etiology","volume":"51","author":"R\u00fccker","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0150","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0155","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.502076_bib0160","first-page":"18","article-title":"Imaging techniques in atherosclerosis","volume":"33 Suppl 1","author":"Escobar Cervantes","year":"2021","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.nrleng.2026.502076_bib0165","article-title":"Planificaci\u00f3n del tratamiento hipolipemiante en la enfermedad vascular ateroescler\u00f3tica. Consenso SEC\/SEA\/SEEN\/SEMFYC\/SEMERGEN\/SEMG\/SEN\/SEACV\/S.E.N","volume":"37","author":"Fern\u00e1ndez-Olmo","year":"2025","journal-title":"Cl\u00edn Investig Arterioscler"},{"key":"10.1016\/j.nrleng.2026.502076_bib0170","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1253\/circj.CJ-12-1149","article-title":"Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study","volume":"77","author":"Nohara","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11910-022-01197-4","article-title":"Lipid-modifying therapies and stroke prevention","volume":"22","author":"Hackam","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2026.502076_bib0185","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0190","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0195","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.502076_bib0200","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0205","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10557-022-07343-x","article-title":"Implications of ACC\/AHA versus ESC\/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI","volume":"37","author":"Vallejo-Vaz","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.nrleng.2026.502076_bib0210","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3390\/jcm14072340","article-title":"Assessing LDL-C levels and lipid-modifying therapies in a real-world cohort of patients with atherosclerotic cardiovascular disease: the REALITY study","volume":"14","author":"Campuzano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0215","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.2672","article-title":"Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain","volume":"43","author":"Campuzano","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.nrleng.2026.502076_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9","volume":"34","author":"German","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.nrleng.2026.502076_bib0240","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Molr Ther Nucleic Acids"},{"key":"10.1016\/j.nrleng.2026.502076_bib0245","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.nrleng.2026.502076_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100503","article-title":"Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11","volume":"14","author":"Koenig","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FJC.0000000000001712","article-title":"Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: an updated network meta-analysis","volume":"86","author":"Burnett","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0260","series-title":"Ficha t\u00e9cnica Leqvio 284 mg - Soluci\u00f3n inyectable enjeringa precargada","year":"2025"},{"key":"10.1016\/j.nrleng.2026.502076_bib0265","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIRCULATIONAHA.119.043406","article-title":"Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model","volume":"141","author":"Brandts","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2026.502076_bib0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11883-024-01271-x","article-title":"Inclisiran, reasons for a novel agent in a crowded therapeutic field","volume":"27","author":"Di Giacomo-Barbagallo","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"10.1016\/j.nrleng.2026.502076_bib0275","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.mayocp.2024.03.025","article-title":"Effects of inclisiran in patients with atherosclerotic cardiovascular disease: a pooled analysis of the ORION-10 and ORION-11 randomized trials","volume":"99","author":"Wright","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nrleng.2026.502076_bib0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.18087\/cardio.2023.10.n2560","article-title":"Inclisiran in patients with acute ischemic stroke: first data","volume":"63","author":"Cherepianskii","year":"2023","journal-title":"Kardiologiia"},{"key":"10.1016\/j.nrleng.2026.502076_bib0285","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0290","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jvs.2008.06.044","article-title":"Occam\u2019s razor: Intervene early to prevent more strokes!","volume":"48","author":"Naylor","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.nrleng.2026.502076_bib0295","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nrleng.2026.502076_bib0300","series-title":"Optimitzaci\u00f3 de laprevenci\u00f3 secund\u00e0ria de la S\u00edndrome Coron\u00e0ria Aguda.Versi\u00f3n 2024","year":"2025"},{"key":"10.1016\/j.nrleng.2026.502076_bib0305","first-page":"390","article-title":"Uso de agentes hipolipemiantes y cumplimiento de metas terap\u00e9uticas en pacientes de alto riesgo cardiovascular en la Rep\u00fablica Argentina","volume":"89","author":"Sigal","year":"2021","journal-title":"Rev Argent Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0310","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.recesp.2016.05.013","article-title":"Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posici\u00f3n de la Sociedad Espa\u00f1ola de Cardiolog\u00eda","volume":"69","author":"Anguita S\u00e1nchez","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.nrleng.2026.502076_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106738","article-title":"Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment","volume":"190","author":"Masana","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nrleng.2026.502076_bib0320","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502076_bib0325","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400112","article-title":"Long-term cognitive safety of achieving very low LDL cholesterol with evolocumab","volume":"4","author":"Zimerman","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.nrleng.2026.502076_bib0330","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1161\/STROKEAHA.121.034576","article-title":"Lipid-Lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors","volume":"52","author":"Sanz-Cuesta","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2026.502076_bib0335","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000346751.39886.01","article-title":"Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study","volume":"72","author":"Goldstein","year":"2009","journal-title":"Neurology"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:03:38Z","timestamp":1783695818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2173580826000829"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502076","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus statement and clinical recommendations on the practical management of lipid-lowering therapy in stroke and transient ischaemic attack","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2026.502076","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502076"}}